Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
M?rquez-Garb?n DC, Yanes CD, Llarena G, Elashoff D, Hamilton N, Hardy M, Wadehra M, McCloskey SA, Pietras RJ. Manuka Honey Inhibits Human Breast Cancer Progression in Preclinical Models. Nutrients. 2024 Jul 22; 16(14).
-
Adekiya TA, Hudson T, Bakare O, Ameyaw EE, Adebayo A, Olajubutu O, Adesina SK. PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer. Biomed Pharmacother. 2024 Aug; 177:117125.
-
Chuang TD, Ton N, Rysling S, Khorram O. In Vivo Effects of Bay 11-7082 on Fibroid Growth and Gene Expression: A Preclinical Study. Cells. 2024 Jun 24; 13(13).
-
Chuang TD, Ton N, Manrique N, Rysling S, Khorram O. Targeting the long non-coding RNA MIAT for the treatment of fibroids in an animal model. Clin Sci (Lond). 2024 Jun 19; 138(12):699-709.
-
Chan AM, Olafsen T, Tsui J, Salazar FB, Aguirre B, Zettlitz KA, Condro M, Wu AM, Braun J, Gordon LK, Ashki N, Whitelegge J, Xu S, Ikotun O, Lee JT, Wadehra M. 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors. Mol Cancer Ther. 2024 Jun 04; 23(6):890-903.
-
Harada E, Yoshida S, Imaizumi Y, Kawamura A, Ohtsuka T, Yoshida K. Dual-specificity tyrosine-regulated kinase 2 exerts anti-tumor effects by induction of G1 arrest in lung adenocarcinoma. Biochim Biophys Acta Gen Subj. 2024 Jun; 1868(6):130600.
-
Inkoom A, Ndemazie NB, Smith T, Frimpong E, Bulusu R, Poku R, Zhu X, Han B, Trevino J, Agyare E. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. BMC Cancer. 2023 May 13; 23(1):435.
-
Shivange G, Mondal T, Lyerly E, Bhatnagar S, Landen CN, Reddy S, Kim J, Doan B, Riddle P, Tushir-Singh J. A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors. Cell Rep. 2021 11 02; 37(5):109953.
-
Wilson T, Pirovano G, Xiao G, Samuels Z, Roberts S, Viray T, Guru N, Zanzonico P, Gollub M, Pillarsetty NVK, Reiner T, Bargonetti J. PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. Mol Pharm. 2021 09 06; 18(9):3418-3428.
-
Li X, Gera L, Zhang S, Chen Y, Lou L, Wilson LM, Xie ZR, Sautto G, Liu D, Danaher A, Mamouni K, Yang Y, Du Y, Fu H, Kucuk O, Osunkoya AO, Zhou J, Wu D. Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. Theranostics. 2021; 11(14):6873-6890.